On June 26, 2012, OJSC Pharmstandard announced the purchase of a controlling stake in Bigpearl Trading Limited (Cyprus). This acquisition of a controlling stake by OJSC Pharmstandard enables it to determine general terms of business activities of OJSC Biomed named after I.I. Mechnikov, Pharmapark LLC and other commercial entities comprising a group of entities which includes Bigpearl Trading Limited. In February 2012, the Company obtained permission from the Federal Antimonopoly Service (FAS) to purchase 50.1% of shares in Cyprus company Bigpearl Trading Limited (Cyprus).
“This acquisition is fully in line with the existing strategy of Pharmstandard in respect of mergers and acquisitions, access to new technologies and production methods, as well as expansion of the current product portfolio of the Company. Addition of new original Rx products to our portfolio allows the Company to venture into new pharmacotherapeutic groups, which consequently leads to an increase in the Company’s organic sales. The transaction is scheduled to be closed at the end of August 2012 and will be financed from Pharmstandard's own funds.” - Igor Krylov, CEO of OJSC Pharmstandard.
“Since, 2009, we have been in close collaboration with Pharmstandard with respect to increasing sales of injectable product Altevir® (recombinant interferon) and today we are happy with the results of this joint effort. Now we are going to work on large-scale projects developing the whole of the product portfolio while drawing on the technological capabilities of both companies, their pool of skills and professionals staff .” - Vasily Srkypin, CEO of Pharmapark LLC.
“We envisage that our collaboration will allow us to start production of new combined vaccines compliant with international standards of good manufacturing practice, to launch an intergrated quality management system and to enhance our current position in the area of product promotion.” - Victor Mikhailov, CEO of Biomed named after I.I. Mechnikov.
Investor Relations Officer
+7 495 970 00 30 ext.2416
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of pharmaceutical products. The main sphere of activity of the enterprises comprising the Pharmstandard group of companies, are developing and manufacturing of high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients. The Pharmstandard group of companies manufactures more than 250 pharmaceutical products, the most well known Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®.
All the production facilities of the Pharmstandard group of companies fully comply with Russian national standards, while six production lines at JSC Pharmstandard-Leksredstva have already received certificates of compliance with the EU GMP standards. All the plants are expected to convert to European GMP standards by 2014, according to the schedule approved by the company's management.
In 2011, total sales amounted to RUR 42,653.9 million, which is 43.7% (RUR 12,967.3 million) above the corresponding 2010 figure.
OJSC Biomed named after I.I. Mechnikov is one of the first Russian producers of vaccines and biological pharmaceutical products with a hundred years of experience of manufacturing and development in the field of immunobiology. The company specialises in manufacturing vaccines, enteric products, interferons, therapeutic and diagnostic allergen products, growth mediums, biologically active probiotic-based food suppliments. In 2011, the company’s revenue amounted to RUR 425 million (excluding VAT).
Pharmapark LLC is a young and vibrant pharmaceutical company created just over ten years ago. The company specialises in manufacturing genetically engineered substances and finished dosage forms made on their basis. It is also the largest manufacturer of recombinant interferon in Russia. The company’s most well-known products are Altevir®(interferon alpha 2b), Epostim® (epoetin beta), the interferon alpha 2b substance.
The company’s management has developed a programme of production certification in compliance with GMP (good manufacturing practice) standards by the end of 2012. Its plans for the near future include further biotechnological developments, including in collaboration with the Ministry of Education and Science of the Russian Federation and the Ministry of Industry and Trade of the Russian Federation, as well as the development and manufacture of new generation biological pharmaceutical products, such as peginterferon, darbepoetin and multicomponent vaccines.
In 2011, the company’s revenue amounted to RUR 883 million (excluding VAT).